Golimumab — a new tool in the armoury against inflammatory arthritis

References

• Brennan FM, Maini RN, Feldmann M. TNF alpha—a pivotal role in rheumatoid arthritis? Br J Rheumatol. 1992;31:293–8.
   PubMedGoogle Scholar
• Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, . Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68:823–7.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, . Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–11.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Martin Mola E, Pedersen R, . Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis. 2009;68:1113–8.
   PubMed Web of Science ®Google Scholar
• Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, . The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford). 2009;48:1283–9.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken). 2010;62:226–34.
   Web of Science ®Google Scholar
• Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, . Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis. 2010;69:1636–42.
   PubMed Web of Science ®Google Scholar
• Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, . Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54:3761–73.
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, . Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–9.
   PubMed Web of Science ®Google Scholar
• Ling J, Lyn S, Xu Z, Achira M, Bouman-Thio E, Shishido A, . Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. J Clin Pharmacol. 2010;50:792–802.
   PubMed Web of Science ®Google Scholar
• Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, . Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47:383–96.
   PubMed Web of Science ®Google Scholar
• Xu Z, Wang Q, Zhuang Y, Frederick B, Yan H, Bouman-Thio E, . Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol. 2010; 50:276–84.
   PubMed Web of Science ®Google Scholar
• Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, . Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:964–75.
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, . E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol. 2009;36:1371–9.
   PubMed Web of Science ®Google Scholar
• Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, . Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010;62:917–28.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, . Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272–83.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Van der Heijde D, Keystone E, Genovese MC, Conaghan PG, . The effect of golimumab on radiographic progression in rheumatoid arthritis: results of the GO-BEFORE and GO-FORWARD randomized, controlled studies. Arthritis Rheum. 2011; in press.
   Google Scholar
• Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, . Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789–96.
   PubMed Web of Science ®Google Scholar
• Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, . Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010;69:1129–35.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, . Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374:210–21.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, . Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–86.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, van der Heijde D, Gladman D, Mease P, McInnes I, Krueger GG, . Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the GO-REVEAL study. ACR Abstract. 2009;LB5.
   Google Scholar
• Kavanaugh A, Mease P, Krueger GG, Gladman D, Zrubek J, Beutler A, . Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104 week efficacy and safety results of the randomised, placebo-controlled GO-REVEAL Study [conference abstract]. ACR Annual Meeting, Philadelphia, 2009. 512.
   Google Scholar
• Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, . Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402–12.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, . Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Care Res (Hoboken). 2010;62:1266–71.
   PubMed Web of Science ®Google Scholar
• Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, . Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49:1056–70.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, . A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009; 179:549–58.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740–51.
   PubMed Web of Science ®Google Scholar
• Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, . Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, . Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005; 64:1414–20.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Highlights of prescribing information. 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125289s006lbl.pdf. Accessed date 8 June 2010.
   Google Scholar
• Cush JJ. Early rheumatoid arthritis—is there a window of opportunity? J Rheumatol Suppl. 2007;80:1–7.
   Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, . A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, . The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, . Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–82.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, . Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381–90.
   PubMed Web of Science ®Google Scholar
• Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, . Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27–35.
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, . Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43.
   PubMed Web of Science ®Google Scholar